Tag: Dermatologic Surgery

All

Revance's investigational injectable—RT002—achieves median duration of 7 months, a phase 2 active comparator study now underway.

The tablet- and smartphone-based tool allows plastic surgeons to generate personalized 3D visualizations during breast augmentation consultations.